List of Ryanodex drug patents

Ryanodex is owned by Eagle Pharms.

Ryanodex contains Dantrolene Sodium.

Ryanodex has a total of 5 drug patents out of which 3 drug patents have expired.

Expired drug patents of Ryanodex are:

  • US9884044
  • US8604072
  • US8110225

Ryanodex was authorised for market use on 22 July, 2014.

Ryanodex is available in for suspension;intravenous dosage forms.

Ryanodex can be used as for use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk..

The generics of Ryanodex are possible to be released after 30 June, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884044 EAGLE PHARMS Treatment using dantrolene
Jun, 2022

(7 months ago)

US8604072 EAGLE PHARMS Treatment using dantrolene
Jul, 2022

(6 months ago)

US8110225 EAGLE PHARMS Treatment using dantrolene
Dec, 2022

(a month ago)

US8685460 EAGLE PHARMS Treatment using dantrolene
Feb, 2023

(12 days from now)

US7758890 EAGLE PHARMS Treatment using dantrolene
Jun, 2025

(2 years from now)

Drugs and Companies using DANTROLENE SODIUM ingredient

Market Authorisation Date: 22 July, 2014

Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic